Skip to main content
. Author manuscript; available in PMC: 2021 Jul 26.
Published in final edited form as: Kidney360. 2021 Mar;2(3):542–557. doi: 10.34067/KID.0005692020

Figure 5. |. Disease modulating regenerative therapies for kidney transplantation address diverse mechanisms and potential clinical benefits.

Figure 5. |

Upper panel: Diverse types of modulatory cellular therapies that have been the subject of early-phase clinical trials in KTx recipients along with their potential sites of action and target cells. Middle panel: Four major mechanistic goals of DMRT applied to KTx with illustration of the most relevant cellular therapies for each, along with their predicted sites of action and most significant cell targets for each (based on preclinical studies and profiling/monitoring analyses of subjects from clinical trial). Lower panel: Significant clinical benefits that represent the most immediate goals for the clinical translation of DMRT in KTx. Figure created using Biorender.com. M-reg, regulatory macrophages; Tol-DC, tolerogenic dendritic cells; T-reg, regulatory T cell.